BSEBoard Meeting5d ago · 13 Nov 2026, 02:13 pm

Outcome of Board Meeting

Natco Pharma Ltd · 524816

✦ AI Summary▲ PositiveResults

Natco Pharma Ltd has announced unaudited financial results for the quarter and half year ended September 30, 2026, along with the declaration of a second interim dividend of Rs. 1.25 per equity share. The company has also provided a consolidated balance sheet as of September 30, 2026.

Analysis Scores

Earnings Impact8/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk4/10
Liquidity Impact9/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Natco Pharma Ltd - 524816 - Board Meeting Outcome for Outcome Of Board Meeting

Attachments (1)

📄

dbcf6652-318c-4a45-85fb-b62b9905fd6f.pdf

pdf

Download →
View document text
November 13, 2026 Corporate Relationship Department The Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd. Mumbai – 400 001. Mumbai – 400 051. Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: Outcome of Board Meeting We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business: 1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time (“Listing Regulations”) along with Limited Review Report of the Statutory Auditors. Please find enclosed herewith a copy of the same for your information. 2. Declared second interim dividend of Rs. 1.25 (Rupees one rupee twenty five paise only) ( 62.50%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2026-27. The date for taking on record of its shareholders eligible for the purpose of payment of second interim dividend i.e., record date is fixed as Thursday, the 19th day of November 2026. The payment of said interim dividend will start from November 27, 2026. A Copy of Press release is also enclosed for your information. Meeting commenced at 11:50 a.m. and concluded at 2:00 p.m. Thanking you Yours faithfully, For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Encl: As above NATCO Pharma Limited Regd. Office: Natco House, Road No. 2,Banjara Hills, Hyderabad, Telangana - 500 034. Phone: +91-40-23547532, Website : www.natcopharma.co.in, CIN: L2423OTG1981PLC003201 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09-2026 in millions except per share Quarter ended Half year ended Year ended S.No Particulars 30-09-2026 30-06-2026 30-09-2025 30-09-2026 30-09-2025 31-03-2026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited Ilncome 1 ln"r"nr" from operations 9,673 7,352 13,630 17,025 26,919 40,783 2 lOther income 521 592 1,000 1,113 1,617 2,976 3 lTotal income (t+z) 10,194 7,9M 't4,630 18,138 28,536 43,7s9 | =ro"n="= lCost of materials consumed 1,717 1,578 1,749 3,295 3,555 5,935 I Purchases of stock-in-trade 818 278 726 1,096 1,099 2,032 lC stoh c" kn -g in" -" t rain d einventories of finished goods, work-in-progress and (704) (s81 ) (778) (1,085) (627) (1,062) lemptoy"e benefits expense 2,036 1,793 2,003 3,829 3,693 6,872 I Finance cosls 176 130 131 306 163 367 lDepreciation, amortisation and impairment expenses 492 471 524 963 1,100 2,066 expenses 3,227 2,219 4,138 5,446 7,697 12,641 lOther expenses 7,762 6,06E 8,493 1 3,850 1 6,680 28,85',1 lTotal 5 Profit before tax and share of profit of associate (3-4) 2,432 1,856 6,137 4,288 1 1,856 14,908 6 I Tax expense (i) Current tax 436 488 1,404 924 2,561 3,035 (ii) Deferred tax (refer note 7) 262 146 (446 408 (6871 (1,846 Total tax expense 698 634 9s8 1,332 1,874 't,189 7 Profit for the period/ year before share of profit of associate (5-6) 1,734 1,222 5,1_79 2,956 9,982 13,719 8 Share of profit of associate (net of tax) 292 843 1,135 466 I Profit for the period/ year (7+8) 2,026 2,065 5,179 4,091 9,982 14,185 10 Other comprehensive income/ (loss) ('OCl') (net of tax) (i), ltems that will not be reclassified to profit or loss: Remeasurement of defined benefit liability/(asset) 1 1 1 1 19 Tax on remeasurement of defined benefit liability/(asset) (7) Fair value changes of Equity investments through OCI 12 103 184 115 237 478 Tax impact on Fair value changes on Equity investments through OCI (1 (1 5) (37 (16) (44 (87) 11 89 148 100 194 403 (ii). ltems that will be reclassified to profit or loss: Exchange differences on translating financial statements of foreign 498 1,088 256 1,586 603 2,518 operations Share of OCI of associate (net of tax) G t6t (71', (47 494 1,021 256 1,s1s 603 2,471 Other comprehensive income for the period/ year, net of tax 505 1 110 404 1,615 797 2,874 11 Total comprehensive income for the period/ year (9+10) 2,531 3,175 5,583 5,706 10,779 1 7,059 12 Profit for the period/year attributable to: Owners of the Company 2,0_26 2 065 5,184 4,0-91 9,991 14,1_85 Non-controlling interests (51 (el 13 Other comprehensive income for the period/ year attributable to: Owners of the Company 505 1,1_10 4-04 1,615 7-97 2,8_74 Non-controlling interests 14 Total comprehensive income for the period/ year attributable to: Owners of the Company 2,5-31 3,1_75 5,588 5,706 1 0,788 17,059 Non-controlling interests (5) (s) 15 Paid-up equity share capital (Face value of ti each) 358 358 358 358 358 358 16 Other equity 91,E53 17 Earnings per share (not annualised for the quarters) (Face value of t2 each) Basic (in {) 11 .31 '1 1.53 28.94 22.84 55.78 79.20 Diluted (in t) 11.31 11.53 28.94 22.84 55.78 79.20 See accompanying notes to lhe unaudited consolidated financial resrults NATCO Pharma Limited Consolidated Balance Sheet: Assets (1) Non-current assets (a) Property, plant and equipment (b) Capital work-in-progress 25,963 25,454 (c) Goodwiil 3,961 2,937 (d) Other intangible assets 644 630 (e) lnvestments accounted for using equity method 1,850 1,943 (f) Financial assets 35,034 22,757 lnvestments (ii) Other financial assets 4,652 2,732 (g) Deferred tax assets, net 3'10 620 (h) Non-current tax assets, net 1,946 2,326 (i) Other non-current assets 129 116 Total non-current assets 699 (2) Gurrent assets (a) Inventories (b) Financial assets 10,062 9,085 lnvestments (ii) Trade receivables 4,483 5,782 (iii) Cash and cash equivalents 8,034 8,812 (iv) Bank balances other than (iii) above 1,385 't,989 (v) Loans 9,305 13,520 't06 (vi) Other financial assets 98 (c) Other current assets 4,502 7,418 Total current assets 3,819 Total assets EQUITYAND LIABILITIES (1) Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company (c) Non-controlling interest Total equity (2) Liabilities (A) Non-current liabilities (a) Financiat liabilities (i) Borrowings (ia) Lease liabilities (ii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (net) Total non-current liabilities (B) Current liabilities (a) Financial liabilities (i) Borrowings (ia) Lease liabilities 6,064 (ii) Trade payables 33 - Totar outstanding dues of micro enterprises and smail enterprises; and 278 -T so mta ar l l o eu nts teta rpn rd isin eg s dues of creditors other than micro enterprises and 3,815 (iii) Other financial liabilities (b) Other current liabilities 1,381 (c) Provisions 1,731 (d) Current tax tiabitities (net) 3,502 Total current liabilities 5 Total liabilities Total equity and liabilities NATCO Pharma Limited Consolidated Statement of Cash Flows: Half year ended 30-09-2026 30-09-2025 (Uanudited) (Uanudited) flows from operating activities before tax for the year for 1 1,856 amortisation and impairment expenses Finance costs 963 't ,1 00 306 163 lnterest income (e1 e) (1,274) for impairment of receivables and advances, net 50 't2 debts written off Loss/ (gain) on sale / discard of property, plant and equipment )/ loss on sale of investments income on equity investment at fair varue through other comprehensive income (2) rd foreign exchange gain, net profit before working capital changes 4,67i in working capital: ' (increase) in inventories (977 (increase) in trade receivables (increase) in other financial assets t (14) (increase) in other assets (665 (131) lncrease/ (decrease) in trade payables 151 2,375 lncrease/ (decrease) in provislons (decrease) in other financial liabilities (2,1se 3,496 rse/ (decrease) in other liabilities 29e 661 (20.' generated from operating activities 72',\ paid, net of refund 2,041 13,90' cash generated from operating activitibs (A) (398 (1.995 flows from investing activities Purchase of property, plant and equipmen [Showing first 8,000 characters — download PDF for full document]